Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 5Sarcoma 1Genitourinary 1Gastrointestinal 1

Conditions

Gastrointestinal Stromal Tumors 3Sarcoma, Synovial 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Recurrence 1Prostatic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Liposarcoma 1Leiomyosarcoma 1Glioblastoma 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Adenocarcinoma of Lung 1

Interventions

pembrolizumab 6Magnetic Resonance Spectroscopy 6Specimen Handling 5Cyclophosphamide 5Radiosurgery 3Oncolytic Virotherapy 3Nivolumab 3Injections 3Gemcitabine 3Drug Therapy 3Biopsy 3fludarabine 2belinostat 2Riluzole 2Paclitaxel 2Ipilimumab 2Filgrastim 2Docetaxel 2Cisplatin 2Celecoxib 2Carboplatin 2Bortezomib 2Blood Specimen Collection 2Amifostine 2AH 111585 2tislelizumab 1spartalizumab 1seribantumab 1selpercatinib 1sargramostim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lung Neoplasms × Midazolam × Sarcoma × Clear all
NCT01402089 2016-02-02

Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients

Cantonal Hospital of St. Gallen

Phase 4 Completed
54 enrolled
GastrointestinalGenitourinarySarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Lung Neoplasms, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡